A clinically integrated translational science programme to progress positive biomarker and therapeutics development for forms of breast cancer currently defined as Triple Negative

Tutt, Andrew (Primary Investigator)
Karagiannis, Sophia (Co-Investigator)
Nestle, Frank (Co-Investigator)
Ng, Tony (Co-Investigator)
Grigoriadis, Anita (Co-Investigator)

Project: Research

Status	Finished
Effective start/end date	15/10/2013 → 31/10/2022

Collaborative partners

King's College London (lead)
Vertex Pharmaceuticals UK

Funding

Breakthrough Breast Cancer: £850,000.00
Breakthrough Breast Cancer: £417,074.00
Breast Cancer Now: £850,000.00
Breakthrough Breast Cancer: £699,999.00
Breakthrough Breast Cancer: £700,000.00
Breakthrough Breast Cancer: £800,000.00